Management

What’s in a name?

ArTara is an abbreviation of the name Arya Tara, given to the only female form of the Buddha. She represents the virtues of health, healing and compassion. Arya Tara reflects our personal and corporate aspirations to fully support the rare-disease patients we treat. Additionally, Arya Tara represents our view that only by reflecting the diversity that characterizes our world can we truly understand and treat rare diseases which often know no boundaries of age, gender, race, religion or background. 

Board of Directors

Luke Beshar

  • • Luke Beshar was the Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals, a global biopharmaceutical Company, from 2007 to 2015
  • • He is the former Chief Financial Officer of various public and private companies and has more than 30 years of general and financial management experience
  • • Mr. Beshar served as Chief Financial Officer of Cambrex Corp. from 2002 to 2007 and previously as Chief Financial Officer at Dendrite Int’l., a provider of services to the life sciences industry
  • • Mr. Beshar began his career with Arthur Andersen & Co. in 1980 and is a CPA. He holds a B.S. degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia
  • • Mr. Beshar is currently a Director of REGENXBIO (NASDAQ RGNX); and a Director of Trillium Therapeutics (NASDAQ TRIL)

Luke Beshar

Luke Beshar

  • • Luke Beshar was the Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals, a global biopharmaceutical Company, from 2007 to 2015
  • • He is the former Chief Financial Officer of various public and private companies and has more than 30 years of general and financial management experience
  • • Mr. Beshar served as Chief Financial Officer of Cambrex Corp. from 2002 to 2007 and previously as Chief Financial Officer at Dendrite Int’l., a provider of services to the life sciences industry
  • • Mr. Beshar began his career with Arthur Andersen & Co. in 1980 and is a CPA. He holds a B.S. degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia
  • • Mr. Beshar is currently a Director of REGENXBIO (NASDAQ RGNX); and a Director of Trillium Therapeutics (NASDAQ TRIL)

Michael Solomon, PhD

Series A Director

  • • Mike is a Venture Partner at SV Health Investors and has over 20 years experience in the biotech industry, the last 14 focused on creating and operating early stage companies
  • • Mike serves as CEO of Ribometrix, a company focused on targeting RNA with small molecules
  • • Most recently he was COO at Decibel Therapeutics, a biotech focused on hearing disorders where he led the creation of Decibel’s business plan and capital raise of $52mm
  • • Previously, he was COO at Ember Therapeutics and CBO at Link Medicine, a CNS company that was sold to Astra Zeneca
  • • Mike was a founder and VP of Discovery at Epizyme Therapeutics and VP of Discovery at Hypnion, Inc a sleep disorder company that was sold to Lilly in 2007 for $325 million
  • • He began his career at Millennium Pharma, where he was project leader for multiple programs
  • • Mike holds a BS, Chemistry from UMass Amherst; PhD, Organic Chemistry, University of Wisconsin and completed postdoctoral work in Synthetic Organic Chemistry, Scripps

Michael Solomon, PhD

Michael Solomon, PhD

Series A Director

  • • Mike is a Venture Partner at SV Health Investors and has over 20 years experience in the biotech industry, the last 14 focused on creating and operating early stage companies
  • • Mike serves as CEO of Ribometrix, a company focused on targeting RNA with small molecules
  • • Most recently he was COO at Decibel Therapeutics, a biotech focused on hearing disorders where he led the creation of Decibel’s business plan and capital raise of $52mm
  • • Previously, he was COO at Ember Therapeutics and CBO at Link Medicine, a CNS company that was sold to Astra Zeneca
  • • Mike was a founder and VP of Discovery at Epizyme Therapeutics and VP of Discovery at Hypnion, Inc a sleep disorder company that was sold to Lilly in 2007 for $325 million
  • • He began his career at Millennium Pharma, where he was project leader for multiple programs
  • • Mike holds a BS, Chemistry from UMass Amherst; PhD, Organic Chemistry, University of Wisconsin and completed postdoctoral work in Synthetic Organic Chemistry, Scripps

Scott Braunstein M.D.

Chairman

• Dr. Braunstein serves as an Operating Partner at Aisling Capital, a leading life sciences investment Firm
• Served as Chief Operating Officer, Chief Strategy Officer, and Senior Vice President of Strategy and Corporate Development at Pacira Pharmaceuticals from 2015 to 2018
• Prior to Pacira, Dr. Braunstein spent 12 years as a Healthcare Analyst and Portfolio Manager at J.P. Morgan Asset Management, where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates
• Dr. Braunstein serves as a Director of Esperion Therapeutics (NASDAQ ESPR), STAT Medical, Trevena, Inc., Marinus Pharmaceuticals, Inc., Ziopharm Oncology, Inc., SiteOne Therapeutics, Inc. and the Cornell Alumni Association for the College of Agriculture and Life Sciences
• Dr. Braunstein received his M.D. from the Albert Einstein College of Medicine and completed his residency in internal medicine at Cornell University-New York Hospital. He received his B.S. from Cornell University

Scott Braunstein M.D.

Scott Braunstein M.D.

Chairman

• Dr. Braunstein serves as an Operating Partner at Aisling Capital, a leading life sciences investment Firm
• Served as Chief Operating Officer, Chief Strategy Officer, and Senior Vice President of Strategy and Corporate Development at Pacira Pharmaceuticals from 2015 to 2018
• Prior to Pacira, Dr. Braunstein spent 12 years as a Healthcare Analyst and Portfolio Manager at J.P. Morgan Asset Management, where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates
• Dr. Braunstein serves as a Director of Esperion Therapeutics (NASDAQ ESPR), STAT Medical, Trevena, Inc., Marinus Pharmaceuticals, Inc., Ziopharm Oncology, Inc., SiteOne Therapeutics, Inc. and the Cornell Alumni Association for the College of Agriculture and Life Sciences
• Dr. Braunstein received his M.D. from the Albert Einstein College of Medicine and completed his residency in internal medicine at Cornell University-New York Hospital. He received his B.S. from Cornell University

Roger Garceau, M.D.

  • • Roger Garceau has more than 30 years of broad pharmaceutical industry in drugs, biologics and combination drug/device products for orphan and non-orphan indications, both in US and Internationally.
  • • Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. since December 2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals was acquired by Shire plc.
  • • At NPS he led two successful orphan products through filing, Advisory Committees and registrations. Previously, he served in several managerial positions with NPS Pharmaceuticals, Inc., Sanofi-aventis and Pharmacia Corporation.
  • • Garceau has been a non-executive director of Enterome SA since December 2016 and Entera Bio since March 2016.
  • • Garceau is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. He holds a B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School.

Roger Garceau, M.D.

Roger Garceau, M.D.

  • • Roger Garceau has more than 30 years of broad pharmaceutical industry in drugs, biologics and combination drug/device products for orphan and non-orphan indications, both in US and Internationally.
  • • Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. since December 2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals was acquired by Shire plc.
  • • At NPS he led two successful orphan products through filing, Advisory Committees and registrations. Previously, he served in several managerial positions with NPS Pharmaceuticals, Inc., Sanofi-aventis and Pharmacia Corporation.
  • • Garceau has been a non-executive director of Enterome SA since December 2016 and Entera Bio since March 2016.
  • • Garceau is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. He holds a B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School.